Related Experiment Video
Updated: Aug 15, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Flow cytometry DNA measurement for prediction of effect of therapy in acute leukemia
1Research Laboratory of Hematology, Second Affiliated Hospital, Hebei Medical College, Shijiazhuang.
Abstract:
We measured the DNA content of bone marrow (BM) aspirate by flow cytometry (FCM) in 41 cases of acute leukemia (AL) and found no remarkable relation between pretreatment DNA index and percentage of proliferative cells and prognosis (P greater than 0.05). After chemotherapy, reduction of proliferative cells rate, disappearance of DNA aneuploidy and decrease of leukemic cells in BM could be considered as the reliable indicators of effective treatment. Complete remission (CR) rate was significantly higher in patients responsive to treatment (81.82%) than in those unresponsive (22.22%; P less than 0.05). It seems that these parameters may serve as indicators of efficiency of chemotherapy and be useful in monitoring regimen in time and in reducing the occurrance of chemotherapy-resistance, thereby facilitating individualization of chemotherapy in AL patients.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025